The Beat Executive Series: Sanofi's Pattern Recognition in Vaccine Development with Deborah Glasser
About Deborah Glasser:
Deborah Glasser holds an MBA in Marketing and Finance from the University of Chicago Booth School of Business and a B.A. with honors from Tufts University. Deborah is currently the Head of Vaccines in North America at Sanofi. In this role, she spearheads a team committed to pursuing scientific breakthroughs, focusing on the development and enhancement of immunizations. Sanofi, a global pharmaceutical giant, places a strong emphasis on innovation, and Deborah plays a crucial role in driving the vision forward, expanding access to vaccines, and advancing public health initiatives throughout the U.S. and Canada.
Drawing on a rich and varied professional background, Deborah brings more than a decade of experience to her current role. Her journey includes an illustrious 13-year tenure at Biogen, where she held diverse positions across its U.S., European, and global organizations. Notably, she played a key role in the successful launch of Tecfidera, an oral multiple sclerosis product that achieved remarkable success, generating $1.3 billion in U.S. sales within its first four full quarters on the market.
Things You’ll Learn:
- The vaccine industry faces intense competition.
- RSV stands as the primary reason for infant hospitalizations.
- Approximately 70 out of every 100,000 individuals end up hospitalized due to the flu.
- The flu poses a significant and serious risk, with an average of 36,000 deaths annually, potentially reaching 98,000 in severe seasons. These deaths are preventable.
- It's crucial to recognize the seriousness of the flu and take preventive measures to avoid unnecessary fatalities.
Resources: